NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.90 +0.88 (+1.13%) GOLD FUTURES
2,392.10 +32.20 (+1.36%) DOW
39,908.00 +349.89 (+0.88%) Bitcoin GBP
51,944.17 +3,412.09 (+7.03%)
NSPR May 2024 5.000 call
| Previous close | 0.3000 |
| Open | 0.3000 |
| Bid | 0.0500 |
| Ask | 0.5500 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.3000 - 0.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 77 |
GlobeNewswireInspireMD Reports First Quarter 2024 Financial Results and Provides Business Update
- Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - - Announced that an abstract detailing one-year outcomes from the C-GUARDIANS IDE clinical trial of CGuard™ Prime has been accepted for presentation at LINC 2024, to be held May 28-31 - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company’s CGUARDIANS II clinical trial for Transcarotid Artery Revascularization (TCAR), as well a
Simply Wall St.InspireMD Insider Ups Holding By 13% During Year
Insiders were net buyers of InspireMD, Inc.'s ( NASDAQ:NSPR ) stock during the past year. That is, insiders bought more...
- GlobeNewswire
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th
-Conference call and webcast to be held at 8:30 a.m. EDT-TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2024 financial results on Tuesday, May 14th, before the financial markets open. Management will host a conference call and webcast with the investment community at 8:30
